Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.

Céline PhanNathalie BenetonJuliette DelaunayZiad ReguiaiClaire BoulardAnne-Claire FougerousseElisa CinottiMarco RomanelliLaure Mery-BossardDomitille Thomas-BeaulieuJosiane ParierFrançois MaccariGuillaume ChabyMarie BastienEdouard BegonMahtab SamimiFrancesca PrignanoAlain BeauchetEmmanuel Mahénull null

Published in: Drugs & aging (2020)

Apremilast seems to be an effective and safe therapeutic option for psoriasis in the elderly. The main AEs reported by patients did not seem to differ from those reported previously in younger populations. However, AEs were more frequent in patients > 75 years old leading to more frequent discontinuation of apremilast compared with younger patients, suggesting a higher level of vigilance is needed in the elderly.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes
middle aged
physical activity